格隆汇12月18日丨永太科技(002326.SZ)在互动平台表示，公司的补锂剂三氟甲基亚磺酸锂等能精准补 充电池活性锂损失，提升循环寿命和能量密度。根据公开资料，该技术旨在适用于多种电池体系，包括 液态、半固态及全固态电池，可以用于电解液补锂、正极补锂和电池修复等场景。公司会持续关注固态 电池等新兴技术领域的发展动态和市场趋势，并基于在含氟精细化学领域的技术积累和产业链优势，积 极进行研发创新和产品布局，探索拓展机会。 ...

格隆汇12月18日丨永太科技(002326.SZ)在互动平台表示，公司氟化液业务已具备产业化基础，并初步 形成小规模订单，目前占整体营收比重较小。根据不同型号的产品性能，公司氟化液产品可以适用于半 导体制造、浸没式数据中心冷却、储能热管理、5G基站热管理和芯片封装等细分场景，近期亦逐步开 始应用于冷板式两相液冷方案中。 ...

一、担保情况概述 浙江永太科技股份有限公司（以下简称"公司"）经 2025 年 5 月 19 日召开 的 2024 年年度股东大会审议通过，同意公司对纳入合并报表范围内的部分子公 司提供累计总额不超过人民币 430,000 万元的担保，该担保额度可循环使用，即 为其向国内各类银行及其他机构的融资（包括但不限于人民币/外币贷款、银行 承兑、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁等）提供连带 责任保证。其中对资产负债率未超过 70%的部分子公司提供担保额度不超过 200,000 万元，对资产负债率超过 70%的部分子公司提供担保额度不超过 230,000 万元。担保额度可在子公司之间进行调剂，但在调剂发生时，资产负债率超过 70%的担保对象，仅能从资产负债率超过 70%的担保对象处获得担保额度。担保 方式包括但不限于保证、抵押、质押，具体担保金额及保证期间按具体合同约定 执行。并授权公司董事长全权代表公司在额度范围内签订担保协议等法律文书及 办理其他相关事宜。详见公司于 2025 年 4 月 28 日在《证券时报》《中国证券报》 《上海证券报》《证券日报》及巨潮资讯网（http://www.cnin ...

Group 1 - The core announcement is that Yongtai Technology's wholly-owned subsidiary, Binhai Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine and Prilocaine Cream from the National Medical Products Administration [2] Group 2 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical sector [2] - This development may lead to increased market opportunities and revenue growth for Yongtai Technology in the future [2]

Core Viewpoint - Yongtai Technology (002326.SZ) has received approval from the National Medical Products Administration for the registration of its compound drug, Ropivacaine and Lidocaine Cream, which is intended for local anesthesia in specific medical procedures [1] Group 1: Product Approval - Yongtai Technology's wholly-owned subsidiary, Binhai Meikang Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Ropivacaine and Lidocaine Cream by the National Medical Products Administration [1] - The cream is a compound formulation of Lidocaine and Ropivacaine, designed for local anesthesia in various situations [1] Group 2: Indications for Use - The cream is indicated for local anesthesia in procedures such as needle punctures (e.g., catheter insertion or blood sampling) [1] - It is also used for superficial surgical procedures, including those involving the genital mucosa and for cleaning/debridement of leg ulcers [1]

Core Viewpoint - Yongtai Technology (002326.SZ) announced that its wholly-owned subsidiary, Binhai Meikang Pharmaceutical Co., Ltd., has recently received the drug registration certificate for Lidocaine and Prilocaine Cream from the National Medical Products Administration [1] Group 1: Product Approval - The drug registration certificate pertains to a compound formulation of Lidocaine and Prilocaine, intended for local anesthesia in specific skin conditions [1] - Indications for the use of the cream include: 1. Needle punctures, such as catheter insertion or blood sampling; 2. Superficial surgical procedures, such as mucosal anesthesia before superficial surgery or infiltration anesthesia; and cleaning/debridement of leg ulcers [1]

Core Viewpoint - Yongtai Technology (002326.SZ) announced that its wholly-owned subsidiary, Binhai Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine and Prilocaine Cream from the National Medical Products Administration [1] Group 1 - The drug, Lidocaine and Prilocaine Cream, is a compound formulation of Lidocaine and Prilocaine [1] - It is indicated for local anesthesia in the following situations: 1. Needle punctures, such as catheter insertion or blood sampling; 2. Superficial surgical procedures, such as mucosal anesthesia before superficial surgery or infiltration anesthesia; and cleaning/debridement of leg ulcers [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江永太科技股份有限公司（以下简称"公司"）全资子公司滨海美康药业 有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"）核准签发 的关于利丙双卡因乳膏的《药品注册证书》，现将有关情况公告如下： | 药品通用名称 | 利丙双卡因乳膏 | | --- | --- | | 英文名/拉丁名 | Lidocaine and Prilocaine Cream | | 规格 | 30g：利多卡因 750mg，丙胺卡因 750mg | | 受理号 | CYHS2303647 | | 证书编号 | 2025S03700 | | 药品批准文号 | 国药准字 H20256194 | | 药品批准文号 至 有效期 | 年 月 日 2030 12 08 | | 药品注册标准 | YBH31092025 | | 编号 | | | 主要成份 | 利多卡因,丙胺卡因 | | 剂型 | 乳膏剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 4 类 | | 药品有效期 24 | 个月 | | 上市许可持有 | ...

证券代码：002326 证券简称：永太科技 公告编号：2025-082 浙江永太科技股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江永太科技股份有限公司（以下简称"公司"）经 2025 年 5 月 19 日召开 的 2024 年年度股东大会审议通过，同意公司对纳入合并报表范围内的部分子公 司提供累计总额不超过人民币 430,000 万元的担保，该担保额度可循环使用，即 为其向国内各类银行及其他机构的融资（包括但不限于人民币/外币贷款、银行 承兑、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁等）提供连带 责任保证。其中对资产负债率未超过 70%的部分子公司提供担保额度不超过 200,000 万元，对资产负债率超过 70%的部分子公司提供担保额度不超过 230,000 万元。担保额度可在子公司之间进行调剂，但在调剂发生时，资产负债率超过 70%的担保对象，仅能从资产负债率超过 70%的担保对象处获得担保额度。担保 方式包括但不限于保证、抵押、质押，具体担保金额及保证期间按具体合同约定 执行 ...

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province, specializing in fluorine fine chemical manufacturing [2][3] - The company operates multiple production bases across Zhejiang, Inner Mongolia, Fujian, and Guangdong, ensuring sufficient capacity to support future growth [3] Financial Performance - In the first three quarters of 2025, the company achieved revenue of CNY 402,835.11 million, a year-on-year increase of 20.65% [4] - The net profit attributable to shareholders was CNY 3,255.39 million, marking a return to profitability [4] Business Segments and Strategies Lithium Battery Materials - The company has established a vertically integrated supply chain for lithium materials, with production capacities as follows: - Solid lithium hexafluorophosphate: approximately 18,000 tons/year - Liquid lithium bis(fluorosulfonyl)imide: 67,000 tons/year (equivalent to 20,000 tons/year in solid form) - Additives: VC at 10,000 tons/year; FEC at 3,000 tons/year - Electrolyte: 150,000 tons/year [5] - Future plans include enhancing R&D and product offerings to meet diverse customer needs [5] Pharmaceutical Sector - The pharmaceutical segment covers key therapeutic areas including cardiovascular, diabetes, central nervous system, anti-infection, and antiviral, with a vertically integrated supply chain for fluorinated intermediates and active pharmaceutical ingredients [6][7] - The company aims to leverage advanced technologies for deeper development in these areas [7] Agricultural Protection - Focused on fluorinated herbicides, fungicides, and insecticides, the agricultural segment is expanding its global market presence through vertical integration and leveraging overseas registration resources [8] - Plans include enhancing production processes and promoting sustainable agricultural solutions [8] Market Dynamics and Pricing - The price fluctuations of key materials like lithium hexafluorophosphate are influenced by supply-demand dynamics, industry competition, and raw material costs [9] - The company employs a market-driven pricing mechanism for lithium materials, adjusting based on market conditions and customer strategies [12] Production Capacity and Utilization - Current VC production capacity stands at 10,000 tons, with 5,000 tons added in November 2025, expected to be gradually released [10] - The company maintains a high capacity utilization rate to ensure timely order fulfillment [10] Segment Performance - In the first three quarters of 2025, the agricultural protection segment saw a revenue increase of 39.77%, while the lithium materials segment experienced a significant growth of 112.09% [17] - The pharmaceutical segment faced challenges with a revenue decline of 30.62% due to patent expirations and increased competition [18] Future Financing Plans - The company maintains stable relationships with banks and financial institutions, planning to assess and pursue financing opportunities aligned with its strategic needs [18]